Levetiracetam Prophylaxis in Brain Tumor Resection Pilot

Sponsor
Hamilton Health Sciences Corporation
Study ID
NCT05897658
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Levetiracetam — DRUG
    Tablets
  • Placebo — OTHER
    Tablets

Study Details

This study aims to evaluate feasibility of a double-blind randomized controlled trial for levetiracetam prophylaxis for prevention of seizure in the perioperative phase of brain tumor resection.

Key Dates

First listed
Jun 9, 2023
Start date
Mar 31, 2025
Status verified
Oct 2024
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Seizure Prophylaxis (Levetiracetam)
    Levetiracetam 1 g taken orally twice a day for 7 days
  • Placebo Comparator: Placebo
    Placebo taken orally twice a day for 7 days

Primary Outcome Measure

Recruitment Rate [ Time Frame: Through study completion, approximately 1 year ]

Central Contacts

Find similar trials

Nationwide
Brain cancer trialsOncology trialsNeuro-oncology trials

Related Studies